-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Society News
-
In Brief for January 10, 2024
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility.
-
IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers
The initiatives include a $2.5 million, 4-year research grant and projects to improve lung cancer biomarker testing uptake around the world.
-
IASLC Calls For Documentation of Tobacco Use in Cancer Clinical Trials
The association recommends collecting data on tobacco use status to advance knowledge on the impacts of tobacco smoke in the context of cancer clinical trials.
-
IASLC Names New Chief Science Officer
Dr. Jennifer King brings expertise in molecular targets for cancer therapeutics as well as executive-level experience implementing strategic initiatives to the scientific affairs team.
-
JTO Continues to Rank Among the Most-Cited Oncology Journals
Editor-in-Chief Dr. Alex Adjei announced the journal’s impact factor once again rose in 2022 and says it remains the leading journal in thoracic oncology.
-
IASLC Announces Results of 2023 Board of Directors Election
The newly elected board members, including President-Elect Dr. Caicun Zhou, will assume their roles at the upcoming 2023 World Conference on Lung Cancer in Singapore.
-
Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye
IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward.
-
IASLC Staging Project Finalizing Recommendations for 9th Edition of TNM Classification System
In a recent interview, Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura provides an update on efforts to further refine the system.
-
Tobacco Control Impacts Everyone in Respiratory Medicine, JTO CRR Editor Says
In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her passion for tobacco control and the importance of open-access journals in elevating research globally.
-
In Brief for Feb. 22, 2023
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership.